Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$166.19 USD

166.19
636,152

+2.02 (1.23%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $166.26 +0.07 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial

by Zacks Equity Research

Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.

3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)

by Zacks Equity Research

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Globus Medical (GMED) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in U.S. Healthcare and International businesses is likely to drive Walgreens' (WBA) first-quarter 2024 performance.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.

Moumi Mondal headshot

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

by Moumi Mondal

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.

Here's Why You Should Invest in Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.

Here's Why You Should Retain Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.

Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.

National Vision (EYE) Store Openings Aid, Macro Issues Stay

by Zacks Equity Research

In terms of store expansion, National Vision (EYE) continues to see sizable new opportunities for many years to come.

David Bartosiak headshot

Bull of the Day: Insulet (PODD)

by David Bartosiak

A big earnings beat at the perfect time has this stock up over 50% in short order.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.

Reasons to Buy Prestige Consumer (PBH) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Prestige Consumer (PBH), backed by the robust strength of its consumer brands portfolio.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of December 25, 2023

by Panel Of Zacks Experts

An Interesting Bet for Trend Investors and a Leading Medical Products Stock for Your Review

Align Technology (ALGN) Up 30% YTD: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN), driven by recent strategic alliance and geographic expansion.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.

Henry Schein (HSIC) Sales Hurt by Cyber Attack, Macro Woes

by Zacks Equity Research

Henry Schein's (HSIC) financial operations are being affected by the current macroeconomic environment.

Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures

by Zacks Equity Research

According to Orthofix (OFIX), this data highlights the noninvasive and cost-effective nature of SpinalStim, enabling patients to continue their healing in the comfort of their homes.

Here's How Much a $1000 Investment in Insulet Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors remain optimistic about Bruker (BRKR) due to the strength of the BSI BioSpin and CALID groups.

Thermo Fisher (TMO) Unveils CorEvitas Pharmacovigilance Platform

by Zacks Equity Research

Thermo Fisher (TMO) introduces the CorEvitas pharmacovigilance platform for clinical research registries.

Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance.

Thermo Fisher's (TMO) PPD Business Backs BARDA's Clinical Trial

by Zacks Equity Research

Thermo Fisher's (TMO) PPD clinical research business is selected by BARDA to support the Phase II platform clinical trial to treat ARDS.

Universal Health (UHS) Up 17% in 3 Months: More Growth Ahead?

by Zacks Equity Research

Universal Health (UHS) is well-poised for growth on the back of the resumption of elective procedures, acquisitions and solid operating cash flows.

Henry Schein (HSIC) Enters Orthopedic Market With New Buyout

by Zacks Equity Research

Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.